The release of PARADIGM-HF trial, with its stunning results for Novartis’ combination drug, is good news for patients with heart failure and their doctors. The trial was ended early because the combination drug, which included sacubitril (an experimental drug) and valsartan (a current therapy), demonstrated superiority over enalapril (another current [...]